Affordability and Sustainability improvements by using new pricing, Cost-Effectiveness and ReimbursemenT models to Appraise iNnovative health technologies

Informazioni relative al progetto

ASCERTAIN

ID dell’accordo di sovvenzione: 101094938

DOI

10.3030/101094938

Data della firma CE 24 Novembre 2022

Data di avvio 1 Dicembre 2022

Data di completamento 30 Novembre 2026

Finanziato da

• Health

Costo totale

€ 4 966 716,00

Contributo UE

€ 4 966 716,00

Coordinato da

ERASMUS UNIVERSITEIT ROTTERDAM
Netherlands

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Documents, reports (3)

Analysis on literature reviews of state-of-the-art.

Report analyzes elements of cost-based and value-based pricing policies, HTA frameworks, thresholds, reimbursement models and payment schemes.

Dissemination, exploitation, and communication plan

This document will set out the principles and main strategies to guide dissemination, exploitation and communication during the project peroid. The plan will be complemented by yearly action plans that specify expected tasks, targets and deadlines.

Project and data management handbook

All relevant project related information for the consortium will be collected in project handbook. It includes general information of agreements, project organizational structure, communication and dissemination practices, internal review, process of deliverables and payments, for example.

Websites, patent fillings, videos etc. (1)

Project website

The project website will be the principle instrument for communication on the project´s objectives and achievements. All partners will be consulted with proposals for the look-and-feel and the structure of the website. During the project period, all partners will contribute with information to population the project website.

Pubblicazioni

Peer reviewed articles (5)

Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab

Autori: R. J. S. D. Heine, F. W. Thielen, R. H. J. Mathijssen, R. W. F. van Leeuwen, M. G. Franken, C. A. Uyl-de Groot
Pubblicato in: PLOS ONE, Numero 19, 2024, ISSN 1932-6203
Editore: Public Library of Science (PLoS)
DOI: 10.1371/JOURNAL.PONE.0293264

Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review

Autori: Nicolas S. H. Xander, Tom Belleman, Maximilian Salcher-Konrad, Anne Hendrickx, Jeffrey Chen, Anne-Sophie Klein Gebbink, Peter Schneider, Kate Morgan, Oliver Groene, Isabelle Durand-Zaleski, Frederick W. Thielen, Carin A. Uyl-de Groot
Pubblicato in: The European Journal of Health Economics, 2025, ISSN 1618-7598
Editore: Springer Science and Business Media LLC
DOI: 10.1007/S10198-025-01834-Y

Microcosting Study of Genomic Profiling for Precision Cancer Medicine

Autori: Pia S. Henkel, Eline Aas, Hege G. Russnes, Ingrid Dyvik, G. Live Fagereng, Åslaug Helland, Hanna Røgenes, Tonje G. Lien, Kine Pedersen
Pubblicato in: The Journal of Molecular Diagnostics, Numero 27, 2025, ISSN 1525-1578
Editore: Elsevier BV
DOI: 10.1016/J.JMOLDX.2025.06.006

Bridging Affordability and Sustainability of Health Innovations via Novel Pricing, Cost-effectiveness, and Reimbursement Models to Improve Patient Access: The ASCERTAIN Project

Autori: Carin A. Uyl-de Groot, Nicolas S.H. Xander, Tom Belleman, Emily A. Burger, Robin Doeswijk, Isabelle Durand-Zaleski, Benjamin P. Geisler, Oliver Groene, Anne Hendrickx, Pia S. Henkel, Renaud Heine, Mirjana Huić, Mauro Melli, Kate Morgan, Monica Racovița, Gauthier Quinonez, Maureen P.M.H. Rutten-van Mölken, Tomáš Tesař, Frederick W. Thielen, Peter Schneider, Yansi Wu, Maximilian Salcher-Konrad, Eline Aas
Pubblicato in: Health Policy and Technology, 2026, ISSN 2211-8837
Editore: Elsevier BV
DOI: 10.1016/J.HLPT.2026.101155

Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands

Autori: Renaud J.S.D. Heine, Ron H.J. Mathijssen, Floor A.J. Verbeek, Chantal Van Gils, Carin A. Uyl-de Groot
Pubblicato in: Value in Health, Numero 27, 2025, ISSN 1098-3015
Editore: Elsevier BV
DOI: 10.1016/J.JVAL.2024.06.003